Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma

Key Points

• This research aims to validate the use of circulating tumor DNA as a biomarker for minimal residual disease detection and monitoring in HPV-negative head and neck squamous cell carcinoma.
• Well powered prospective trials were proposed to assess the clinical utility of circulating tumor DNA.
• Focus on its role in guiding therapeutic intensification and de-escalation strategies.
• Evaluate personalized treatment approaches based on ctDNA results.
• Circulating tumor DNA demonstrated potential as a biomarker for minimal residual disease.
• Need for further validation through clinical trials to determine effectiveness in treatment decisions.

Abstract